GSK and XenoPort's Horizant fails in Phase IIb for migraine prophylaxis
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline and XenoPort's new formulation of gabapentin, Horizant (gabapentin enacarbil, GSK1838262/XP13512), has failed to meet the primary endpoint in a Phase IIb study of improvement over placebo as a prophylactic treatment for migraine headaches, with or without aura. GSK told Scrip that it was probably not going to progress Horizant to Phase III for this indication.